BioCryst Pharmaceuticals, Inc. Debt/Equity

Debt/Equity of BCRX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.


Highlights and Quick Summary

  • Debt/Equity for the quarter ending September 30, 2022 was -2.97 (a 0.6% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Equity decreased by -46.36%
  • Annual Debt/Equity for 2021 was -5.55 (a -61.79% decrease from previous year)
  • Annual Debt/Equity for 2020 was -14.51 (a -1133.36% decrease from previous year)
  • Annual Debt/Equity for 2019 was 1.4 (a 111.73% increase from previous year)
Visit stockrow.com/BCRX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of BioCryst Pharmaceuticals, Inc.

Most recent Debt/Equityof BCRX including historical data for past 10 years.

Interactive Chart of Debt/Equity of BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -2.97 -2.96 -3.73
2021 -5.55 -2.11 -2.82 -3.86 -5.55
2020 -14.51 1.49 0.71 14.88 -14.51
2019 1.4 -1.21 -5.42 2.38 1.4
2018 0.66 0.45 0.49 0.39 0.66
2017 0.31 0.26 1.07 0.66 0.31
2016 16.15 6.35 0.19 0.09 34.05
2015 0.05 0.0 0.0 0.0 0.05
2014 0.0 0.0 0.0 -5.24 0.0
2013 -26.64 8.8 -3.32 -10.56 -26.64
2012 -66.08 3.07 1.92 1.3 -66.08

Business Profile of BioCryst Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology